IPOpulse
Back to Ticker

IPCA Laboratories Limited

NSE: IPCALAB
Healthcare Healthcare
₹1,814.5
-0.99%EOD · 19 Oct

IPCA Laboratories Limited is a listed Healthcare company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap
₹46,035 Cr
52W Range
₹2038 / ₹1252
Volume
168K
52.6% delivery
1Y Return
+36.0%
P/E Ratio
35.5
P/B Ratio
5.8
ROE
13.2%
Debt / Equity
8.49

Peers in Healthcare

Top 8 by market cap
CompanyLTP30DMarket CapP/EP/BROE %Div Yld %
IPCA Laboratories Limited(this stock)₹1,814.5₹46,035 Cr35.55.813.2%0.31%
Divi's Laboratories LimitedDIVISLAB₹9,087₹2.41 L Cr83.014.516.2%0.33%
Torrent Pharmaceuticals LimitedTORNTPHARM₹4,558.7₹1.73 L Cr72.818.417.0%0.83%
Laurus Labs LimitedLAURUSLABS₹2,069₹1.12 L Cr101.821.017.7%0.12%
Zydus Lifesciences LimitedZYDUSLIFE₹1,113.9₹1.11 L Cr25.04.218.3%0.09%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP₹7,700₹1.11 L Cr54.312.021.5%0.25%
Aurobindo Pharma LimitedAUROPHARMA₹1,621.4₹93,292 Cr26.12.69.9%0.00%
Mankind Pharma LimitedMANKIND₹2,253.2₹93,067 Cr46.05.812.4%0.00%
Max Healthcare Institute LimitedMAXHEALTH₹830₹80,785 Cr56.77.714.3%0.23%

Quality Score

Durability · Valuation · Momentum — objective math, not advice
B
58/100
Composite score: 40% quality, 30% valuation, 30% momentum
QualityAverage · 43
ValuationAverage · 45
MomentumStrong · 90
High debt load (D/E 8.5)
In confirmed uptrend (Stage 2)

Technical Indicators

Full analysis · objective math, not advice
Returns
1D
-1.0%
1W
-4.5%
1M
-7.9%
3M
-1.3%
6M
+23.6%
1Y
+36.0%
Weinstein Stage
Stage 2 — Advancing (uptrend)
RSI (14)
27 Oversold
Trend Template
6/7strong
RS vs Nifty (3M)
+6.2pp
Moving Averages (price vs MA)
20-DMA
₹1932
below
50-DMA
₹1917
below
150-DMA
₹1716
above
200-DMA
₹1656
above
From 52W High
-11.0%
From 52W Low
+45.0%
Support (20D)
₹1797
Resistance (20D)
₹2037

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

Community discussion(0)

Sign in to join the discussion.

Sign in

No comments yet — be the first to share your view.